Subtopic Deep Dive

Broadly Neutralizing Antibodies Against HIV
Research Guide

Q: What methods isolate bNAbs?

Single B-cell sorting from elite neutralizers, followed by rational Env design for screening (Wu et al., 2010; Zhou et al., 2010).

Q: What are key bNAb papers?

Wu et al. (2010, Science, 1749 citations) on VRC01 design; Walker et al. (2011, Nature, 1496 citations) on multi-bNAb coverage; Zhou et al. (2010, Science, 1151 citations) on VRC01 structure.

Q: What are open problems in bNAb research?

Inducing bNAbs via vaccination; overcoming glycan shields; extending half-life for therapy (Walker et al., 2011; Rerks-Ngarm et al., 2009).

What is Broadly Neutralizing Antibodies Against HIV?

Broadly neutralizing antibodies (bNAbs) are human monoclonal antibodies that neutralize diverse HIV-1 strains by targeting conserved epitopes on the Env glycoprotein.

Isolation of bNAbs from infected donors has identified potent antibodies like VRC01 and PG9. Structural studies reveal their binding to CD4-binding site and glycan-V3 loops (Zhou et al., 2010; Wu et al., 2010). Over 10 key papers from 1996-2011 report bNAb discovery and testing, with 1700+ citations each.

Curated Papers

Key Challenges

Why It Matters

bNAbs neutralize >90% of HIV-1 strains, guiding vaccine design to mimic germline precursors (Wu et al., 2010; Walker et al., 2011). Passive infusion trials show viral load suppression in humans. Vaccine trials like RV144 used Env immunogens to elicit partial responses (Rerks-Ngarm et al., 2009). These enable prevention of transmitted founder viruses (Keele et al., 2008).

Key Research Challenges

Epitope Shielding by Glycans

HIV Env glycans mask conserved sites, hindering bNAb access (Walker et al., 2011). Rare bNAbs evolve via extensive somatic hypermutation to penetrate shields. Vaccine immunogens fail to induce such mature antibodies.

Germline Targeting

bNAbs derive from rare B cells with specific germline genes (Wu et al., 2010). Initial immunogens do not engage these precursors effectively. Sequential boosting strategies are needed for affinity maturation.

Clinical Translation Barriers

Passive bNAb infusions require frequent dosing due to short half-lives. Combination therapies needed for full coverage (Zhou et al., 2010). Vaccine induction of bNAbs remains unsuccessful in trials (Rerks-Ngarm et al., 2009).

Essential Papers

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

Tatjana Dragic, Virginia Litwin, Graham P. Allaway et al. · 1996 · Nature · 3.2K citations

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

Supachai Rerks‐Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan et al. · 2009 · New England Journal of Medicine · 3.0K citations

This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk. Vaccination did not affect the viral load or CD4+...

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

Brandon F. Keele, Elena Giorgi, Jesus F. Salazar-Gonzalez et al. · 2008 · Proceedings of the National Academy of Sciences · 1.9K citations

The precise identification of the HIV-1 envelope glycoprotein (Env) responsible for productive clinical infection could be instrumental in elucidating the molecular basis of HIV-1 transmission and ...

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

Xueling Wu, Zhi-Yong Yang, Yuxing Li et al. · 2010 · Science · 1.7K citations

Designer Anti-HIV Developing a protective HIV vaccine remains a top global health priority. One strategy to identify potential vaccine candidates is to isolate broadly neutralizing antibodies from ...

Broad neutralization coverage of HIV by multiple highly potent antibodies

Laura M. Walker, Michael Huber, Katie J. Doores et al. · 2011 · Nature · 1.5K citations

Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals

Ruth I. Connor, Kristine E. Sheridan, Daniel J. Ceradini et al. · 1997 · The Journal of Experimental Medicine · 1.4K citations

Recent studies have identified several coreceptors that are required for fusion and entry of Human Immunodeficiency Virus type 1 (HIV-1) into CD4+ cells. One of these receptors, CCR5, serves as a c...

Mucosal vaccines: the promise and the challenge

Marian R. Neutra, Pamela A. Kozlowski · 2006 · Nature reviews. Immunology · 1.2K citations

Reading Guide

Foundational Papers

Start with Wu et al. (2010) for bNAb rational design (1749 citations); Zhou et al. (2010) for VRC01 crystal structure; Walker et al. (2011) for potency coverage. These establish core antibodies and epitopes.

Recent Advances

Study Keele et al. (2008) on founder Envs for transmission relevance; Rerks-Ngarm et al. (2009) RV144 trial for vaccine context (3009 citations).

Core Methods

B-cell isolation, Env trimer design, cryo-EM structures, neutralization panels with TCLA and primary isolates (Wu et al., 2010; Zhou et al., 2010).

How PapersFlow Helps You Research Broadly Neutralizing Antibodies Against HIV

Discover & Search

Research Agent uses searchPapers and exaSearch to find bNAb isolation papers, then citationGraph traces impact of Wu et al. (2010) to 1749 citing works on Env engineering. findSimilarPapers expands to VRC01 analogs from Zhou et al. (2010).

Analyze & Verify

Analysis Agent applies readPaperContent to parse Wu et al. (2010) abstracts for neutralization breadth stats, verifyResponse with CoVe cross-checks claims against 5 related papers, and runPythonAnalysis computes IC50 distributions across strains using GRADE for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in germline-targeting strategies from Walker et al. (2011), flags contradictions in RV144 trial data (Rerks-Ngarm et al., 2009). Writing Agent uses latexEditText, latexSyncCitations for bNAb review manuscripts, latexCompile for Env structure figures, exportMermaid for epitope evolution diagrams.

Use Cases

"Plot neutralization potency of VRC01 vs PG9 across 200 HIV strains from papers."

Research Agent → searchPapers('VRC01 PG9') → Analysis Agent → readPaperContent(Zhou et al. 2010, Walker et al. 2011) → runPythonAnalysis(pandas IC50 aggregation, matplotlib heatmap) → researcher gets CSV/figure of breadth comparison.

"Draft LaTeX review section on bNAb epitopes with citations."

Synthesis Agent → gap detection('bNAb epitopes') → Writing Agent → latexEditText('CD4 site glycans') → latexSyncCitations(Wu et al. 2010) → latexCompile → researcher gets compiled PDF section.

"Find code for HIV Env modeling from bNAb structure papers."

Research Agent → citationGraph(Zhou et al. 2010) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets verified PyMOL scripts for VRC01 docking.

Automated Workflows

Deep Research workflow scans 50+ bNAb papers via searchPapers → citationGraph → structured report on epitope classes from Wu et al. (2010). DeepScan applies 7-step CoVe to verify RV144 vaccine claims (Rerks-Ngarm et al., 2009) with GRADE scoring. Theorizer generates hypotheses for glycan-trimming immunogens from Walker et al. (2011) structures.

Try Doxa for Broadly Neutralizing Antibodies Against HIV Research

Frequently Asked Questions

What defines a broadly neutralizing HIV antibody?

bNAbs neutralize >50% of diverse HIV-1 strains at IC50 <1 μg/ml, targeting conserved Env sites like CD4-binding region (Wu et al., 2010).

What methods isolate bNAbs?

Single B-cell sorting from elite neutralizers, followed by rational Env design for screening (Wu et al., 2010; Zhou et al., 2010).

What are key bNAb papers?

Wu et al. (2010, Science, 1749 citations) on VRC01 design; Walker et al. (2011, Nature, 1496 citations) on multi-bNAb coverage; Zhou et al. (2010, Science, 1151 citations) on VRC01 structure.